Citigroup Analyst Revises Price Target for ACADIA Pharmaceuticals
On March 12, 2024, Citigroup analyst David Hoang reiterated his positive outlook on ACADIA Pharmaceuticals (NASDAQ: ACAD) with a Buy ...
Tag: ACAD
Oppenheimer Analyst Reaffirms Perform Rating and 25 Price Target for ACADIA Pharmaceuticals
On February 5, 2024, Jay Olson, an analyst at Oppenheimer, restated his belief in ACADIA Pharmaceuticals (NASDAQ: ACAD) by giving ...
Popular News
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
-
NextGen Healthcare Charts Course for Behavioral Health Transformation
-
Regulatory Shift Sparks Potential Breakthrough for DeFi Technologies
